Navigation Links
ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410
Date:1/7/2009

FREDERICK, Md., Jan. 7 /PRNewswire/ -- ImQuest Life Sciences announced today the successful submission of an IND application to the Food and Drug Administration to initiate human clinical trials for their lead pyrimidinedione HIV inhibitor IQP-0410. ImQuest anticipates initiating their Phase 1 studies in the first quarter of 2009. IQP-0410 is a novel small molecule inhibitor of HIV which primarily acts as a nonnucleoside reverse transcriptase inhibitor (NNRTI). The compound possesses a second mechanism of action which prevents the entry of HIV into target cells and significantly raises the potential genetic barrier to resistance with IQP-0410 therapy. Preclinical pharmacokinetic and toxicology studies have demonstrated the potential for once per day dosing and a high safety margin for the compound. IQP-0410 has been found to inhibit HIV replication at sub-nanomolar concentration levels and to have highly significant activity against all clinical virus strains evaluated as well as against multi-drug resistant virus strains obtained from patients failing long courses of therapy with currently approved RT and protease inhibitors. The compound is well suited for use as a component of primary HAART regimens as well as a salvage therapy option. Preclinical studies have also demonstrated the ability of the compound to be used in combination with all other approved HIV drugs.

"The submission of this IND represents a critical milestone in the therapeutic development of the pyrimidinedione class of molecules as potential new HIV drugs and an important success in the strategic drug development initiatives between ImQuest and Samjin Pharmaceutical Co. Ltd of Seoul, KOREA," said Dr. Robert W. Buckheit, Jr., Executive Vice President and Chief Scientific Officer of ImQuest Life Sciences. "We believe that IQP-0410 will be a new and novel addition to the armamentarium of HIV drugs available and provide HIV-infected individuals with a safe and effective alter
'/>"/>

SOURCE ImQuest Life Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine technology :

1. ImQuest Receives Two Year Phase 2 SBIR Grant to Develop Pyrimidinedione Product as an Anti-HIV Topical Microbicide
2. ImQuest Scientists Present Important HIV Microbicide Development Results at Microbicides 2008 in Delhi, India
3. ImQuest Publishes Results of Important Structure Activity Relationship Program on Dual Acting Pyrimidinediones
4. Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children
5. U.S. Naval Medical Research Center Resubmits IND Application for Proposed Op RESUS Clinical Trial in Trauma Patients in the Battlefield Setting
6. Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings
7. Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
8. U.S. Navy Submits Protocol for Field Trauma Trial of Hemopure(R)
9. AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six
10. AdvanDx Submits Yeast Traffic Light PNA FISH(TM) for FDA 510(k) Clearance for Detection of Candida species in Positive Blood Cultures
11. AstraZeneca Submits sNDA for NEXIUM(R) I.V. for Peptic Ulcer Bleed Indication
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... , May 21, 2013 Sanofi (EURONEXT: ... REGN) today announced that the New England Journal ... study results of dupilumab (SAR231893/REGN668) in patients with moderate-to-severe ... the alpha subunit of the interleukin 4 receptor (IL-4R ... drivers of Th2 (Type 2 helper T cell) immune ...
(Date:5/21/2013)... -- U.S. spending on specialty prescription drugs — those ... multiple sclerosis and rheumatoid arthritis — is projected to ... to a forecast released today by Express Scripts (NASDAQ: ... "As we see what,s on the horizon, ... so they can continue to offer an affordable pharmacy ...
(Date:5/21/2013)... , May 21, 2013  AcelRx Pharmaceuticals, ... specialty pharmaceutical company focused on the development ... treatment of acute and breakthrough pain, today ... placebo-controlled Phase 3 study of its investigational ... (NanoTab System), the primary efficacy endpoint was ...
Breaking Medicine Technology:Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 2Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 4Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 5Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 6Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 7U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 2U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 3U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 4U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 5Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 2Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 3Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 4Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 5Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 6Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 7Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 8Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 9Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 10
... REDWOOD CITY, Calif., May 6, 2011 AcelRx Pharmaceuticals, ... company focused on the development and commercialization of innovative ... today announced that Richard King, President and Chief Executive ... Research Conference at the San Francisco Ritz Carlton. The ...
... MIAMI, May 6, 2011 SaveRxCanada.com the premier Canadian pharmacy ... still purchase Canada drugs from a Canada pharmacy ... Canada drugs can be 85% less than the U.S. ... clientele since 2002. 2. Convenience – Many patients are ...
Cached Medicine Technology:AcelRx Pharmaceuticals to Present at the JMP Securities Research Conference 2Canadian Pharmacy Intermediary's Top Reasons U.S. Customers Choose Canada Online Pharmacies Revealed by SaveRxCanada.com 2
(Date:5/21/2013)... (PRWEB) May 21, 2013 The nation’s ... lawsuit is nearing its conclusion in Washington state ... during closing statements yesterday, an attorney for the Plaintiffs ... company wanted to tie sales and services for its ... training to keep control of surgeons, to keep control ...
(Date:5/21/2013)... May 21, 2013 Go Classy Tours, ... that they have redesigned their website featuring N ... pool, hot tubs, bars and dining. The website, which ... including sales and guest reviews, will now have a ... itself, including pages on culinary local recipes, flora and ...
(Date:5/21/2013)... 21, 2013 While North Carolina is ... comprehensive travel guides. Brunswick Plantation & Golf Resort is ... include access to 27 holes of "Top10" championship golf. ... North Carolina, knowing the Top 10 from ... away the overwhelming task of selecting the course to ...
(Date:5/21/2013)... About one in six Australian couples suffer infertility, ... one of the fastest growing industries in the health ... conceive naturally through a variety of treatment options, the ... (IVF) cycles. Over the past five years, the number ... 4.4% per annum to a forecast 40,000 cycles in ...
(Date:5/21/2013)... Reporter , , TUESDAY, May 21 (HealthDay News) -- Swollen ... apnea in children, and while removing them did not ... did help them with sleep, behavior and quality of ... a condition that causes abnormal pauses in breathing during ... with the surgery, and those improvements were likely responsible ...
Breaking Medicine News(10 mins):Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 2Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 3Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 4Health News:The Oldest and Original Nudist Travel Agency for NResort Announced Today a Redesigned Website Featuring Information on Culinary Events, Flora and Fauna, and Photography 2Health News:Brunswick Plantation & Golf Resort Named in Top 10 Golf Resorts in North Carolina 2Health News:Fertility Clinics in Australia Industry Market Research Report Now Available from IBISWorld 2Health News:Fertility Clinics in Australia Industry Market Research Report Now Available from IBISWorld 3Health News:Removing Tonsils Helps Kids With Sleep Apnea, Study Finds 2Health News:Removing Tonsils Helps Kids With Sleep Apnea, Study Finds 3
... Video games are now being considered seriously as a medical ... from obesity and dementia to cancer.// ,In the United ... and government policy makers to launch their ‘games for health’ ... video games as a treatment option by incorporating ...
... Needle phobia or fear of needles can be overcome ... according to researchers at the University of New Mexico's// ... of needles can impact the care a patient receives. ... sight of needles, whereas some adults avoid the doctor's ...
... The latest Government report in UK, states that British public ... third of the population will be obese within the next ... published by the Department of Health, earlier in the week, ... children would get very dangerously fat, and on all probabilities, ...
... Snaith, a couple travelling on a My Travel flight to ... son in Tenerife after the captain// of the plane refused ... on his head. The captain thought it was chicken pox. ... his mom had an interview to attend. My Travel's agent, ...
... King Jr./Drew Medical Center explained, that in the wake ... back the accreditation along with// restoration of the cut ... Epps, chief executive of the hospital, also spoke highly ... inculcate a sense of responsibility for the quality of ...
... breast cancer test, which could save several women from needless ... core needle biopsy to sample suspect breast tissue for microscopic ... of gene patterns in the sample. This may help in ... test has very little proof. ,Till date, the ...
Cached Medicine News:Health News:Britons Are Bloating! 2Health News:Britons Are Bloating! 3Health News:Novel test for diagnosis of breast cancer 2
The Foundation PS knee offers a femoral option and tibial insert which provides a specially designed cam action that engages at 60 degrees of flexion to induce a smooth stable femoral roll-back motio...
... Natural Knee design includes several ... CSTi porous coating option for ... a unique bone preserving posterior ... groove to maximize range of ...
... Total Knee System provides anatomical replacement of ... while preserving the stabilizing Anterior and Posterior ... motion of the knee. All the components ... sizes and are equally proportioned and contoured ...
Advance Posterior Stabilized Total Knee systems improves patellofemoral kinematics, reduces wear rate potential, increases resistance to posterior tibial dislocation, achieves at least 120o flexion i...
Medicine Products: